Our
Pipeline
We bring more than 35 years of innovation to the ADC field. Our lead program, mirvetuximab soravtansine, is a first-in-class ADC in Phase 3 development for platinum-resistant ovarian cancer and we have a number of ADCs in development in our clinical and early stage pipelines.
Compound
Early Stage
Preclinical
Phase 1
Phase 2
Phase 3
Mirvetuximab Soravtansine
TARGET: Folate receptor alpha (FRa)
Forward I: Ovarian Monotherapy
FORWARD II: Ovarian COMBO; with bevacizumab
FORWARD II: Ovarian COMBO; with carboplatin and bevacizumab
IMGN632
TARGET: CD123
BPDCN and AML
IMGN151
TARGET: FRα
ovarian next generation
IMGC936
TARGET: ADAM9
MacroGenics
Co-Development
partnerships
In addition to our own, proprietary pipeline of ADC candidates, we have a number of partnerships and collaborations in place that leverage our technology – and those of our collaborators – to address unmet medical needs. We continually seek innovative partnerships with the goal of advancing science, gaining access to complimentary capabilities, strengthening our financial position, and creating more value for ImmunoGen.
Examples of our partnerships include a strategic cross-licensing agreement with CytomX Therapeutics to develop ProbodyTM drug conjugate (PDC) therapies, a co-development and co-promotion collaboration with MacroGenics to develop a first-in-class ADAM9-targeting ADC, and a strategic collaboration and option agreement with Jazz Pharmaceuticals to develop and commercialize hematology-related ADCs.
legacy platform deals
Our technology platform has been the basis for a number of high-value partnerships for the company, including the first-ever ADC approved as a treatment option for HER2-positive breast cancer, which is marketed by Roche, called Kadcyla®.
In addition to Roche, we have ADC technology deals in place with Amgen, Bayer, Biotest, Sanofi, and Takeda.
